Zogenix, Inc. announced the expansion of its senior leadership team in support of the planned launch of Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules in March 2014. This includes the appointment of a Chief Medical Officer, Vice President of Medical and Scientific Affairs, and Executive Director of Medical Affairs, effective immediately. The new senior appointments are all distinguished leaders in the fields of pain management and analgesic drug development and will play key roles in the launch and post marketing support of Zohydro ER, as well as building the company's product pipeline targeting CNS disorders and pain management.

Bradley S. Galer, M.D., Executive Vice President and Chief Medical Officer, prior to joining Zogenix, Dr. Galer served as President of the Pain Group at Nuvo Research. Arnold R. Gammaitoni, Pharm.D., Vice President, Medical and Scientific Affairs, prior to joining Zogenix, Dr. Gammaitoni served as Vice President of Scientific Affairs of the Pain Group at Nuvo Research. Marsha R. Stanton, Ph.D., RN, Executive Director, Medical Affairs, prior to joining Zogenix, Dr. Stanton served as Executive Director of Program Development, External Affairs, Medical Affairs at Horizon Pharma.